Indomethacin vs ibuprofen: comparison of efficacy in the setting of conservative therapeutic approach

Malikiwi, Andra; Roufaeil, Charlene; Tan, Kenneth; Sehgal, Arvind

doi:10.1007/s00431-014-2441-0

Cited by 9 publications

(4 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Considering observational studies, all 24 studies had a cohort design. Based on the Newcastle-Ottawa Quality Assessment Scale for this type of study design, 12 studies obtained a score of 9 out of [79-81, 84, 89, 91, 93-95, 97, 99, 101], nine had a score of [83,85,86,88,92,96,98,100,102], two studies a score of 7 [82,87], and one a score of 6 [90] (Appendix 6).…”

Section: Risk Of Biasmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy and safety of pharmacological treatments for patent ductus arteriosus closure: A systematic review and network meta-analysis of clinical trials and observational studies

Marconi

Bettiol

Ambrosio

et al. 2019

Pharmacological Research

View full text Add to dashboard Cite

Efficacy and safety profiles of different pharmacological interventions used to treat patent ductus arteriosus (PDA) are relatively unexplored. Integrating the findings of randomized clinical trials (RCTs) with those from observational studies may provide key evidence on this important issue.We aimed at estimating the relative likelihood of failure to close the PDA, need for surgical closure, and occurrence of adverse events among preterm and full-term infants treated with indomethacin, ibuprofen, or acetaminophen, placebo, or no treatment including both RCTs and observational studies.We searched PubMed, Embase, and the Register of Controlled Trials from inception to October 30, 2018. We first estimated proportions of subjects with failure to close the PDA, subjects in whom surgical closure was performed after pharmacological treatment, death, and subjects with selected adverse events (AEs). These estimates were obtained using frequentist random-effect meta-analysis of arm-specific proportions. We then compared active drugs with each other and with control (either placebo or no treatment) by summarizing results at the end of treatment reported in the papers, regardless of number of administration(s), dose, route and type of administration, and study design and quality. We also summarized primary outcome results separately at first, second and third cycles of treatment. These estimates were obtained using Bayesian random-effects network meta-analysis for mixed comparisons, and frequentist random-effect pairwise meta-analysis for direct comparisons.We included 64 RCTs and 24 observational studies including 14,568 subjects (5339 in RCTs and 9229 in observational studies, 8292 subjects received indomethacin, 4761 ibuprofen, 574 acetaminophen, and 941 control (including placebo or no intervention).The proportion of subjects with failure to close the PDA was 0.24 (95% Confidence Interval, CI: 0.20, 0.29) for indomethacin, 0.18 (0.14, 0.22) for ibuprofen, 0.19 (0.09, 0.30) for acetaminophen, and 0.59 (0.48, 0.69) for control . At end of treatment, compared to control, we found inverse associations between all active drugs and failure to close PDA (for indomethacin Odds Ratio, OR, was 0.17 [95% Credible Interval,

show abstract

Section: Risk Of Biasmentioning

confidence: 99%

“…This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors [16,19,32,38,66]; 12 [21,43]; 13 [34,36,42,48,68,76,81,91,95,96,101]; 14 [34]; 15 [37,40];…”

Section: Author Contributionsmentioning

confidence: 99%

Efficacy and safety of pharmacological treatments for patent ductus arteriosus closure: A systematic review and network meta-analysis of clinical trials and observational studies

Marconi

Bettiol

Ambrosio

et al. 2019

Pharmacological Research

View full text Add to dashboard Cite

show abstract

“…123 A comparison between indomethacin and ibuprofen showed comparable efficacy and safety. 124 Alongside with indomethacin, diclofenac potassium also is a NSAID included in the silver line of antiinflammatory drugs against SARS-CoV2 infection. 123 Recent reports showed that diclofenac potassium increases lymphocyte recruitment for the immune response against SARS-CoV2.…”

Section: Other Affordable Nsaidsmentioning

confidence: 99%

“…The use of indomethacin to relieve pain and discomfort has been compared to other NSAIDs even in past reports; for example, indomethacin has no anaesthetic properties with respect to diclofenac, 122 yet recent evidence recommends to better target COX‐2 and use panels of drugs against COVID‐19 including indomethacin, diclofenac and celecoxib 123 . A comparison between indomethacin and ibuprofen showed comparable efficacy and safety 124 …”

Section: Nsaids As the First Choice Recommended Drugs In The Covid‐19...mentioning

confidence: 99%

Home pharmacological therapy in early COVID‐19 to prevent hospitalization and reduce mortality: Time for a suitable proposal

Pandolfi

Chirumbolo

Ricevuti

et al. 2021

Basic Clin Pharma Tox

View full text Add to dashboard Cite

The COVID-19 pandemic is a highly dramatic concern for mankind. In Italy, the pandemic exerted its major impact throughout the period of February to June 2020. To date, the awkward amount of more than 134,000 deaths has been reported. Yet, post-mortem autopsy was performed on a very modest number of patients who died from COVID-19 infection, leading to a first confirmation of an immune-thrombosis of the lungs as the major COVID-19 pathogenesis, likewise for SARS. Since then (June-August 2020), no targeted early therapy considering this pathogenetic issue was approached. The patients treated with early anti-inflammatory, anti-platelet, anticoagulant and antibiotic therapy confirmed that COVID-19 was an endothelial inflammation with immuno-thrombosis. Patients not treated or scarcely treated with the most proper and appropriate therapy and in the earliest, increased the hospitalization rate in the intensive care units and also mortality, due to immunethrombosis from the pulmonary capillary district and alveoli. The disease causes widespread endothelial inflammation, which can induce damage to various organs and systems. Therapy must be targeted in this consideration, and in this review, we demonstrate how early anti-inflammatory therapy may treat endothelia inflammation and immune-thrombosis caused by COVID-19, by using drugs we are going to recommend in this paper.

show abstract

Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants

Ohlsson

Walia

Shah

2018

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

show abstract

Indomethacin vs ibuprofen: comparison of efficacy in the setting of conservative therapeutic approach

Abstract: Indomethacin was more efficacious for ductal closure although did not impact outcomes. Use of staging schema may help understand 'need to treat' and refine therapy.

Cited by 9 publications

References 33 publications

Efficacy and safety of pharmacological treatments for patent ductus arteriosus closure: A systematic review and network meta-analysis of clinical trials and observational studies

Efficacy and safety of pharmacological treatments for patent ductus arteriosus closure: A systematic review and network meta-analysis of clinical trials and observational studies

Home pharmacological therapy in early COVID‐19 to prevent hospitalization and reduce mortality: Time for a suitable proposal

Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants

Contact Info

Product

Resources

About